source
- AstraZeneca to acquire worldwide rights to Dizal's lung cancer drug Zegfrovy for $600 millionAstraZeneca announced it will pay $600 million upfront to Dizal Pharmaceutical for the worldwide development and sales rights to the lung cancer drug Zegfrovy. The agreement gives AstraZeneca full…
- Celcuity receives FDA approval for Revtorpyk breast cancer therapyCelcuity, a small public biotech, announced that the U.S. Food and Drug Administration has cleared its drug Revtorpyk for use in breast cancer patients when combined with fulvestrant. The approval…